Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL

NCT06832228 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG: Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）

Sponsor

Zhejiang Cancer Hospital